The Patent Finder

Actavis, Inc.

Also on record
Records under this name other than patents Actavis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Actavis, Inc.

PatentTitleStatus Expires Confidence
US 7,959,946Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,785,627Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Term ended Jul 31, 2026 · From the USPTO record
Term endedTerm ended Jul 31, 2026From the USPTO record
US 9,060,941Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Term ended
Ended no later than Mar 11, 2025 · Low confidence
Term endedEnded no later than Mar 11, 2025Low confidence
US 8,470,368Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Term ended Nov 1, 2023 · From the USPTO record
Term endedTerm ended Nov 1, 2023From the USPTO record
US 8,309,125Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Ended no later than Sep 19, 2023 · From the USPTO record
Term endedEnded no later than Sep 19, 2023From the USPTO record
US 8,668,931Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Formerly held
Term ended
Ended no later than Sep 19, 2023 · From the USPTO record
Term endedEnded no later than Sep 19, 2023From the USPTO record
US 8,551,516Administration of non-oral androgenic steroids to women
Formerly held
Term ended
Term ended Aug 31, 2022 · From the USPTO record
Term endedTerm ended Aug 31, 2022From the USPTO record
US 6,630,166Compositions for conjugated estrogens and associated methods
Formerly held
Term ended
Term ended Feb 12, 2022 · From the USPTO record
Term endedTerm ended Feb 12, 2022From the USPTO record
US 8,597,683Modified release tranexamic acid formulation
Formerly held
Lapsed on the fee record
Ended Dec 3, 2021 · From the USPTO record
Lapsed on the fee recordEnded Dec 3, 2021From the USPTO record
US 9,387,178Modified release tranexamic acid formulation
Formerly held
Lapsed on the fee record
Ended Jul 12, 2020 · From the USPTO record
Lapsed on the fee recordEnded Jul 12, 2020From the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited